InVivo Therapeutics Holdings Corp. (NVIV) today announced that
InVivo CEO Mark Perrin has been featured on The Wall Street Transcript
(TWST), a service for investors and industry researchers that provides
fresh commentary and insight through interviews with CEOs. The candid
conversation about the company and InVivo’s Neuro-Spinal Scaffold was
released on August 4 and is part of TWST’s company interview series. The
full interview is available on InVivo’s website at http://www.invivotherapeutics.com/investor-relations/news/in-the-news/.
“We were honored to have InVivo selected as one of The Wall Street
Transcript’s featured companies,” Mr. Perrin said, “Personally, I was
happy to have the chance to talk about developments at InVivo, not the
least of which is the technology itself. We’ve achieved some important
milestones this year, including getting a top-notch leadership team in
place and the initiation of our clinical program. I talk about those
milestones – and others – in the interview, as well as our plans going
forward.”
He added, “This kind of exposure is important to our goal of
disseminating information to investors and to potential patients.
Everything we’re doing at InVivo, ultimately, is for the patient, and to
improve their quality of life after the devastation of a spinal cord
injury. We appreciate The Wall Street Transcript helping us get the word
out about this exciting technology.”
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and
biotechnology company with a focus on treatment of spinal cord injuries.
The company was founded in 2005 with proprietary technology co-invented
by Robert Langer, ScD, Professor at Massachusetts Institute of
Technology, and Joseph P. Vacanti, MD, who is affiliated with
Massachusetts General Hospital. In 2011 the company earned the David S.
Apple Award from the American Spinal Injury Association for its
outstanding contribution to spinal cord injury medicine. The
publicly-traded company is headquartered in Cambridge, MA. For more
details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements within the
meaning of the federal securities laws. These statements can be
identified by words such as "believe," "anticipate," "intend,"
"estimate," "will," "may," "should," "expect" and
similar expressions. Any forward-looking statements contained herein are
based on current expectations, and are subject to a number of risks and
uncertainties. Factors that could cause actual future results to differ
materially from current expectations include, but are not limited to,
risks and uncertainties relating to the Company’s ability to
successfully open additional clinical sites for enrollment; the
timing of the Institutional Review Board process; the Company’s ability
to obtain FDA approval to commercialize its products; the Company’s
ability to develop, market and sell products based on its technology;
the expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the availability of
substantial additional funding for the Company to continue its
operations and to conduct research and development, clinical studies and
future product commercialization; and other risks associated with the
Company’s business, research, product development, regulatory approval,
marketing and distribution plans and strategies identified and described
in more detail in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2013, as amended, and its other filings with the SEC,
including the Company’s Form 10-Qs and current reports on Form 8-K. The
Company does not undertake to update these forward-looking statements.
Copyright Business Wire 2014